Ultragenyx Pharmaceutical Inc
General ticker "RARE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.5B
Ultragenyx Pharmaceutical Inc follows the US Stock Market performance with the rate: 31.2%.
Estimated limits based on current volatility of 2.2%: low 42.20$, high 44.06$
Factors to consider:
- North America accounted for 77.4% of revenue in the fiscal year ended 2022-12-31
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [26.89$, 59.91$]
- 2024-12-30 to 2025-12-30 estimated range: [25.60$, 56.18$]
Financial Metrics affecting the RARE estimates:
- Negative: Non-GAAP EPS, $ of -8.33 <= 0.10
- Negative: Operating profit margin, % of -56.72 <= 1.03
- Negative: Operating cash flow per share per price, % of -13.07 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Inventory ratio change, % of 0.75 <= 1.08
Short-term RARE quotes
Long-term RARE plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $351.41MM | $363.33MM | $434.25MM |
| Operating Expenses | $733.14MM | $1,012.25MM | $1,003.46MM |
| Operating Income | $-381.74MM | $-648.92MM | $-569.21MM |
| Non-Operating Income | $-71.24MM | $-52.81MM | $-39.26MM |
| Interest Expense | $29.42MM | $43.02MM | $66.00MM |
| R&D Expense | $497.15MM | $705.79MM | $648.45MM |
| Income(Loss) | $-452.98MM | $-701.73MM | $-608.46MM |
| Taxes | $1.04MM | $5.70MM | $-1.82MM |
| Profit(Loss) | $-454.02MM | $-707.42MM | $-606.64MM |
| Stockholders Equity | $922.56MM | $352.49MM | $275.41MM |
| Inventory | $16.23MM | $26.77MM | $33.97MM |
| Assets | $1,522.40MM | $1,545.44MM | $1,491.01MM |
| Operating Cash Flow | $-338.69MM | $-380.46MM | $-474.81MM |
| Capital expenditure | $73.09MM | $146.12MM | $46.77MM |
| Investing Cash Flow | $-195.37MM | $-291.65MM | $168.00MM |
| Financing Cash Flow | $118.55MM | $501.21MM | $388.14MM |
| Earnings Per Share* | $-6.70 | $-10.12 | $-8.25 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.